Autism spectrum disorder (ASD) is a common neurodevelopmental condition characterized by marked genetic heterogeneity. Recent studies of rare structural and sequence variants have identified hundreds of loci involved in ASD, but our knowledge of the overall genetic architecture and the underlying pathophysiological mechanisms remains incomplete. Glycine receptors (GlyRs) are ligand-gated chloride channels that mediate inhibitory neurotransmission in the adult nervous system but exert an excitatory action in immature neurons. GlyRs containing the α2 subunit are highly expressed in the embryonic brain, where they promote cortical interneuron migration and the generation of excitatory projection neurons. We previously identified a rare microdeletion of the X-linked gene GLRA2, encoding the GlyR α2 subunit, in a boy with autism. The microdeletion removes the terminal exons of the gene (GLRA2 Δex8-9 ). Here, we sequenced 400 males with ASD and identified one de novo missense mutation, p.R153Q, absent from controls. In vitro functional analysis demonstrated that the GLRA2 Δex8-9 protein failed to localize to the cell membrane, while the R153Q mutation impaired surface expression and markedly reduced sensitivity to glycine. Very recently, an additional de novo missense mutation (p.N136S) was reported in a boy with ASD, and we show that this mutation also reduced cell-surface expression and glycine sensitivity. Targeted glra2 knockdown in zebrafish induced severe axon-branching defects, rescued by injection of wild type but not GLRA2 Δex8-9 or R153Q transcripts, providing further evidence for their loss-of-function effect. Glra2 knockout mice exhibited deficits in object recognition memory and impaired long-term potentiation in the prefrontal cortex. Taken together, these results implicate GLRA2 in non-syndromic ASD, unveil a novel role for GLRA2 in synaptic plasticity and learning and memory, and link altered glycinergic signaling to social and cognitive impairments.
INTRODUCTION
Autism spectrum disorder (ASD) is a clinically and genetically heterogeneous neurodevelopmental condition defined by impairments in social communication and interaction, accompanied by repetitive behaviors and restricted interests. Rare and very rare copy number variants (CNVs) and sequence variants, both inherited and de novo, affecting hundreds of loci have been implicated in ASD. [1] [2] [3] [4] [5] Many of these variants involve genes on the X chromosome, 2 which may partially explain the excess of affected males over females observed in ASD (4:1). To date, nearly 100 X-linked genes have been associated with intellectual disability and other neurodevelopmental disorders, including autism, primarily in hemizygous males. 6 A large number of genes implicated in syndromic and non-syndromic ASD are involved in synaptic function, highlighting this as a convergent pathway dysregulated in ASD. 7 However, despite recent advances, the underlying genetic determinants are unknown in the majority of cases and our understanding of the pathophysiological mechanisms leading to ASD remains incomplete.
Glycine receptors (GlyRs) are members of the Cys-loop ion channel superfamily that also includes γ-aminobutyric acid type A (GABA A ), nicotinic acetylcholine and serotonin 5-HT3 receptors. GlyR typically consists of pentameric combinations of alpha (α1-α4) and beta (β) subunits forming a central pore that selectively controls transmembrane flux of chloride. 8 Functional GlyRs can be formed as homomers comprising five α subunits, or as heteromers comprising α and β subunits. Each subunit contains a large N-terminal extracellular domain, which harbors the ligand-binding 1 site, and four transmembrane domains, termed TM1-TM4. In humans, GLRA1, GLRA2 and GLRA3 encode α subunits (GLRA4 is a pseudogene), while GLRB encodes the β subunit. GlyR α subunits exhibit distinct spatial and temporal expression patterns in the central nervous system (CNS). The α2 subunit is widely expressed in embryonic and perinatal CNS and expression markedly decreases after birth, 9, 10 suggesting a role for α2-containing GlyR in neuronal development. By contrast, α1 and α3 GlyRs mediate the majority of glycinergic neurotransmission in the adult spinal cord and brain stem, where they are involved in hyperekplexia (startle disease) 11 and inflammatory pain, 12 respectively. GlyR α3 is also expressed in the hippocampus, where it has been implicated in temporal lobe epilepsy. 13 Although known as the main inhibitory neurotransmitters in the adult CNS, glycine and GABA have a depolarizing and excitatory action in immature neurons due to the inverted chloride gradient during development. 14, 15 At these early stages, embryonic GlyRs and GABA A receptors are located extrasynaptically and can be tonically activated by paracrine release of endogenous agonists. 14, 16, 17 The subsequent increase in intracellular Ca 2+ generates spontaneous electrical activity that can shape neuronal network formation. 18 The developmental role of GABA in neuronal proliferation, migration and differentiation has been widely documented, [19] [20] [21] and a growing body of evidence supports similar neurotrophic effects for glycine in the developing CNS [22] [23] [24] [25] [26] and retina. 27 In particular, recent studies have demonstrated the role of GlyR α2 in proliferation and neuronal migration during cortical development. 25, 26 As part of a large CNV screen in ASD, 28 we previously identified a rare microdeletion of GLRA2 in a boy with autism, absent from controls. Here, we screened a cohort of 400 males with ASD for GLRA2 sequence variants and identified a de novo missense mutation, R153Q. We next examined the cell-surface localization and electrophysiological properties of the deleted (GLRA2 Δex8-9 ) and mutated (R153Q) GLRA2 proteins in transfected Chinese hamster ovary (CHO) cells to assess the functional impact of the mutations. We also characterized an additional, recently described de novo missense GLRA2 mutation 5 in CHO cells. Using molecular modeling, we further investigated the effect of the R153Q mutation on receptor function. To determine the functional consequences of the ASD-related GLRA2 mutations in vivo, we knocked down glra2 expression in zebrafish embryos and performed rescue experiments with human wild-type and mutated GLRA2 transcripts. Finally, we investigated the effects of Glra2 disruption on behavior and synaptic plasticity in mice. Overall, our results implicate the GLRA2 gene in ASD and link alterations in glycine-mediated signaling to the social and cognitive dysfunction associated with ASD.
MATERIALS AND METHODS Subjects
Patients were recruited by the Paris Autism Research International Study (PARIS) at specialized clinical centers in France and Sweden. 29 All patients were evaluated by psychiatrists and diagnosed based on clinical evaluation and DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) criteria. Subjects were assessed with the Autism Diagnostic Interview-Revised and the Asperger Syndrome Diagnostic Interview; 30 those recruited more recently were also assessed with the Autism Diagnostic Observation Schedule. At the time of inclusion, patients were screened for genetic disorders associated with autism; investigations included karyotype, molecular genetic testing for fragile X syndrome and metabolic screening; brain imaging and electroencephalography were performed when possible. In addition, subjects were screened for microdeletion/microduplication syndromes using multiplex ligationdependent probe amplification and/or chromosomal microarray analysis. Patients with known genetic disorders were excluded from subsequent analysis. All families provided informed consent and the research was approved by the ethics committees of the participating institutions (Comité de Protection des Personnes Ile-de-France VI, Paris, France, and Ethical Review Board in Gothenburg, Sweden).
The sample of 400 independent males screened for GLRA2 mutations included 334 probands from simplex families and 66 from multiplex families (with two or more affected siblings); 336 met diagnostic criteria for autism, 44 for Asperger syndrome and 20 for pervasive developmental disorder not otherwise specified; 42% had very limited or no language; 62% had intellectual disability (IQo 70); and 8.5% had a history of epilepsy. The mean age at inclusion was 11.8 years (3-39 years). Most patients were Caucasian (90%).
Mutation screening
All GLRA2 coding exons and intron-exon boundaries were PCR-amplified and sequenced using DNA extracted from blood or B lymphoblastoid cell lines (see Supplementary Methods for details). Where mutations were shown to have arisen de novo, we verified maternity and paternity by genotyping both parents and the subject at several microsatellite loci.
Reference sequences
GenBank accession numbers for genomic and protein sequences for GLRA2 are NM_002063.3 and NP_002054.1, respectively. Note that amino-acid sequence numbering is given with the signal peptide; residues are numbered starting at the initiator methionine, in accordance with the nomenclature recommendations of the Human Genome Variation Society (http://www.hgvs.org). The first amino acid after signal peptide cleavage is residue number 28. Genomic locations are based on GRCh37/hg19.
Accession numbers for genomic and protein sequences for Glra2 in mice are NM_183427.4 and NP_906272.1, and for glra2 in zebrafish NM_001167899.1 and NP_001161371.1.
GLRA2 constructs
GLRA2 cDNA was generated from human hippocampus poly A + RNA (Clontech, Mountain View, CA, USA) and cloned into pEGFP-N1 vector (Clontech) using NotI, which excises the enhanced green fluorescent protein (EGFP) coding sequence. Mutations were performed using the QuikChange II site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions, and positive clones were identified by DNA sequencing. The GLRA2 truncated mutant was produced to end at amino acid 310, immediately followed by six amino acids (VRNLA*), resulting in a 316-amino-acid truncated protein, like in Patient 1 (Figure 2a ). For the GLRA2 construct mimicking the mutation in Patient 2, the arginine residue at position 153 was changed to glutamine (R153Q) (Figure 2a ). For the additional de novo missense mutation reportedly recently in an ASD patient, 5 the asparagine at position 136 was changed to serine (N136S). CHO cells were co-transfected with the different GLRA2 constructs and EGFP cDNA using FuGENE 6 Transfection Reagent (Roche, Indianapolis, IN, USA). CHO cells were recorded or immunolabeled 48 h after transfection. Cells were routinely tested for mycoplasma contamination.
Whole-cell recordings
Whole-cell patch-clamp recordings of transfected CHO cells were performed at room temperature using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, USA) in saline solution containing (in mM): 126 NaCl, 1.2 NaH 2 PO 4 , 4.5 KCl, 10 glucose, 2 CaCl 2 , 1 MgCl 2 and 10 HEPES (pH 7.2). Patch-clamp electrodes (4-6 MΩ) contained an internal solution with the following composition (in mM): 130 CsCl, 4 MgCl 2 , 4 Na 2 ATP, 10 EGTA and 10 HEPES (pH 7.2). Transfected cells were selected according to their EGFP expression under UV light. Data were low-pass filtered at 2 kHz, digitized at 20 kHz with a Digidata 1322 A interface, and acquired using PClamp 10 software (Molecular Devices). Glycine was applied using a 0.5-mm-diameter quartz tubing positioned 1 mm away from the recording area. 17 The quartz tubing was connected using a manifold to reservoirs filled with saline solution or with different concentrations of glycine (solution exchange times ⩽ 30 ms). Different glycine concentrations were applied to CHO cells expressing wild-type or mutant GlyR α2 subunits to control possible amplitude rundown. All compounds were purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France). Analyses were performed off-line with PClamp 10 software or Axograph X.1.3.5 software (AxoGraph Scientific, Sydney, Australia).
Immunohistochemistry
Transfected CHO cells were immunolabeled using goat polyclonal antibodies against the 18 N-terminal amino acids of the human GlyR α2 subunit (GlyR α2 N-18: SC-17279; Santa Cruz Biotechnology, Santa Cruz, CA, USA). For details see Supplementary Methods.
Cell-surface biotinylation
Surface proteins of transfected CHO cells were biotinylated using the Pierce Cell Surface Protein Isolation Kit (Thermo Scientific, Rockford, IL, USA) and analyzed using western blotting. For details see Supplementary Methods.
Molecular modeling of the GlyR α2 homomer
Fold recognition of human GlyR α2 subunit was performed with HHPred. 31 The structure of the Caenorhabditis elegans glutamate-gated chloride channel α (GluCl) (PDB: 3RIF) was identified as the best template. A profileprofile alignment between the human GlyR α2 subunit and the C. elegans GluCl α subunit (chain A) was generated using MUSCLE web server (www. ebi.ac.uk/Tools/msa/muscle), resulting in 42% sequence identity. Based on this alignment, 50 homology models of human GlyR α2 subunit were built using MODELLER-9v10 (http://salilab.org/modeller/) and assessed with the DOPE statistical potential score. The model based on the lowest score (Zscore = -0.174) was selected. Additional evaluation using the ProSA web server (https://prosa.services.came.sbg.ac.at/prosa.php) showed that the model quality (Z-score = -4.95) fell within a range typically found for native proteins of similar size, demonstrating the high quality and reliability of the model. Using the Chimera molecular visualization and analysis software (http://www.cgl.ucsf.edu/chimera/), a glycine molecule was docked into an approximate position within the predicted binding site, using structural information about the binding of glutamate in the GluCl obtained from the crystal structure (PDB: 3RIF), and experimental evidence of residues in GlyR α1 that are known to interact with the glycine ligand. 32 The substitution R153Q was modeled into the GlyR α2 homology model using the swapaa command, taking into account the highest rotamer probability (based on the Dunbrack backbone-dependent rotamer library), the highest number of H-bonds and the lowest clash score.
Zebrafish analyses
For knockdown analysis of zebrafish glra2, two-cell stage wild-type zebrafish embryos were injected with antisense morpholino oligonucleotides directed against the glra2 translation initiation site (glra2 MO) at 1 pmol per embryo and analyzed at 28 h post-fertilization by standard immunostaining procedures. For rescue experiments, the wild-type, mutated and deleted versions of human GLRA2 transcripts were co-injected at 100 pg in one-cell stage zebrafish embryos together with the glra2 MO. Additional details are given in the Supplementary Methods.
Mice
Glra2 mutant mice were generated by TND and RJH and maintained in our laboratory in Paris on a C57BL/6J background (see Supplementary Methods). Only males were used for the behavioral, molecular and electrophysiological studies. All mice were between 9 and 20 weeks of age at the start of the behavioral experiments. All experiments were conducted in accordance with the European Communities Council Directive (86/609/ EEC) and approved by the local animal ethics committee (Comité d'éthique en expérimentation animale Charles Darwin, C2EA-05).
Behavioral assays
Glra2 hemizygous (Glra2 ) littermates were housed in groups of three to four per cage (33 × 15 × 13 cm) with free access to food and water in a temperature-and humidity-controlled animal facility maintained on a 12-h light/dark cycle. Sample size was chosen based on previous experience with behavioral assays. All tests were performed blind to genotype. Cages and subjects within a cage were tested in a random order. A detailed description of experimental procedures is provided in the Supplementary Methods.
Ex-vivo electrophysiology Male Glra2
− /Y mice and wild-type littermates were decapitated and the brain was rapidly removed from the skull. Coronal slices (400 μm) containing the prelimbic area (1.94-2.8 mm from the bregma) were sectioned with a vibratome (Campden Instruments, Loughborough, UK) in chilled oxygenated (95% O 2 /5% CO 2 ) artificial cerebrospinal fluid containing in mM: 124 NaCl, 2 KCl, 26 NaHCO 3 , 1.15 KH 2 PO 4 , 1 MgCl 2 , 2 CaCl 2 and 11 D-glucose. Slices were allowed to recover in oxygenated artificial cerebrospinal fluid at room temperature for at least 3 h before recording. Experiments were performed in a submersion recording chamber with continuous perfusion (1 ml min
Experiments were conducted in the following order: recording of stable baseline field excitatory postsynaptic potentials (fEPSPs) for at least 20 min, delivery of high-frequency stimulation (50 pulses at 100 Hz, 5 times with 3 min interval) to induce plasticity, followed by response monitoring for 50 min post-conditioning. The stimulating and recording electrodes were both placed on the surface of layer I-II, as described. 33 Single stimulations (monophasic constant current square pulses; 100 μs width) were applied through a bipolar stimulating electrode (teflon-coated tungsten, A-M Systems, Sequim, WA, USA). Recordings were made with glass micropipettes filled with 3 M NaCl. fEPSPs were evoked at 0.033 Hz, and the response size was set at 60% of the maximum amplitude, which was about 0.7-0.8 mV with 30-40 μA stimulus intensities. All evoked responses were fed to an amplifier in current-clamp mode and digitized at 10 kHz through a Digidata 1322 A interface (Molecular Devices) using Elphy dataacquisition software (CNRS, Gif sur Yvette, France). The initial slope of the EPSP (1 ms period from its onset, mV/ms) was calculated for each individual EPSP as previously described. 33 Statistical comparisons between the averaged slopes of the last 10 min after high-frequency stimulation and the baseline responses were performed for each genotype using Wilcoxon's matched-pairs signed ranks test.
Statistics
Values are shown as mean ± s.e.m. Data were analyzed using unpaired two-tailed Student's t-test (with equal or unequal variance, as appropriate) or analysis of variance (ANOVA). The Mann-Whitney U test was used where data were not normally distributed. Time-course data without normal distribution were analyzed by two-way repeated-measures ANOVA after data transformation. Analysis of ex vivo electrophysiological data was performed using Wilcoxon's signed ranks test. Statistical analyses were carried out using Prism 5 (GraphPad Software, San Diego, CA, USA). Full statistical tests are presented in Supplementary Table S6 .
RESULTS

GLRA2 mutations in ASD patients
In a genome-wide CNV study of 996 ASD individuals using Illumina 1M SNP microarrays, 28 we identified a microdeletion of GLRA2 (chrX:14693216-14836199, hg19) in a boy with non-syndromic autism (Patient 1). This boy had language delay with functional language, and low average IQ (verbal IQ 93, performance IQ 75 and full-scale IQ 82); the physical exam was normal, with no dysmorphic features (see Supplementary Clinical Description for further details). The deletion was inherited from his healthy mother, consistent with X-linked recessive transmission. The 151 kb deletion (GLRA2 Δex8-9 ) encompasses the last two exons of GLRA2 (Figure 1a) , and is predicted to result in loss of transmembrane domains TM3 and TM4. The deletion was validated using quantitative PCR and the breakpoint was localized to intron 7 after sequencing the junction fragment (Figures 1b and c, and Supplementary Figure S1 ). The end points of the deletion arose in regions lacking extensive homology, suggesting that this is a non-recurrent event. Reverse transcription of mRNA from blood samples of Patient 1 and his mother, followed by GLRA2 cDNA amplification, demonstrated the presence of a truncated transcript, indicating the mutated allele escapes nonsensemediated mRNA decay (Supplementary Figures S2a-c) . The deletion of the last two exons results in the incorporation of intron 7, leading to a stop codon, as shown by RNA sequencing (Supplementary Figure S2d) . The translation product would terminate with five additional amino acids followed by a stop codon (VRNLA*) (Supplementary Figure S2d) . The patient's mother had a normal, non-skewed X chromosome inactivation pattern Table S1 ), indicating that GLRA2 deletions are very rare events.
To further delineate the role of GLRA2 mutations in ASD, we used direct sequencing to investigate the coding regions and splice site junctions of this gene in 400 affected males. We identified a de novo missense mutation, c.458G4A, leading to the amino-acid substitution p.R153Q in one subject (Figure 1d) . Patient 2 had non-syndromic autism, severe language delay with functional language, mild intellectual disability (verbal IQ 63, performance IQ 67 and full-scale IQ 63), and generalized tonicclonic seizures starting at 18 years (Supplementary Clinical Description). No clinically relevant copy number variant (CNVs) were identified in this patient. The patient has an older sister with autism who does not carry the GLRA2 mutation (Supplementary Clinical Description), which suggests intrafamilial heterogeneity, a common finding among multiplex families with autism 34 and not unexpected given the profound etiological heterogeneity underlying ASD and the high rate of the disorder. The mutation affects a highly conserved amino-acid residue, unchanged in protein sequences of GLRA2 in vertebrates, as well as in GLRA1 and GLRA3 in humans (Figure 1e ). This change was predicted to be damaging by PolyPhen-2, SNPs&GO, MutPred, PANTHER and SIFT (Supplementary Table S3 ). The R153Q substitution was absent from 404 unaffected fathers of ASD probands from our cohort, and was not listed in dbSNP (build 138), the 1000 Genomes database or the Exome Variant Server (Supplementary Table S2 ). In total, the p.R153Q mutation was absent from 18349 control X chromosomes. Furthermore, the mutation has not been reported in 4032 cases with ASD, or in 3302 patients with schizophrenia, intellectual disability or epilepsy from previous studies (Supplementary Table S2 ). No other likely pathogenic mutations in GLRA2 were identified in our 400 ASD males (Supplementary  Table S4 ), in 44000 males with ASD or other neurodevelopmental disorders, or in 5029 male controls (Supplementary Table S2 ). Since the completion of our studies, an additional de novo missense mutation in GLRA2 (p.N136S) was reported in a male with ASD in a whole-exome sequencing study of over 2500 simplex families. 5 This mutation affects a highly conserved residue Table S3) . A missense variant (p.R350L) predicted to be damaging was reported in a female with ASD 35 (Supplementary Tables S2 and  S3) , and was inherited from her healthy mother, consistent with our observation that GLRA2 mutations are not associated with a phenotype in females. Likewise, three missense variants reported in healthy males in the Exome Variant Server are predicted to be benign by the majority of in silico prediction tools, whereas potentially damaging missense variants are only reported in heterozygous females (Supplementary Table S3 ).
GLRA2 mutations have loss-of-function effects in vitro
We used in vitro studies to analyze the functional impact of the GLRA2 exon 8 − 9 deletion and R153Q substitution found in ASD patients. We generated truncated (GLRA2 Δex8-9 ) and mutated (GLRA2 R153Q ) constructs as shown in Figure 2a , and co-transfected them with EGFP cDNA in CHO cells. As TM3 and TM4 are crucial for anchoring of the protein to the membrane, we predicted that the GLRA2 Δex8-9 truncated mutant would exhibit loss of membrane localization. Consistent with this, the wild-type and GLRA2 R153Q proteins were both observed at the plasma membrane of ) was produced to end at amino acid 310, immediately followed by six amino acids (VRNLA*), resulting in loss of two transmembrane domains, as in Patient 1. In the mutant construct (GLRA2 R153Q ), Arg153 was mutated to glutamine as in Patient 2. The first and last amino acids are numbered; the signal peptide and the four transmembrane domains are shown in dark blue and orange, respectively. Confocal cross-sections show surface expression of wildtype and mutant GLRA2 proteins in non-permeabilized cells. GLRA2 R153Q localized properly to the plasma membrane, as shown by the punctiform staining of GlyR α2 at the cell surface, whereas GLRA2 Δex8-9 failed to traffic to the membrane. Scale bar, 10 μm. Rare GLRA2 mutations in autism M Pilorge et al transfected cells, whereas GLRA2 Δex8-9 was undetectable at the cell surface (Figure 2a ) and was mislocalized to the cytoplasm in permeabilized cells (Supplementary Figure S3) . To determine whether the GLRA2 R153Q mutation affected the number of GlyR α2 on the cell surface, we isolated biotinylated surface receptors and analyzed them by western blotting. GLRA2 R153Q induced a 56% decrease in surface expression compared to wild-type GLRA2 (Supplementary Figure S4) . Quantification of the intracellular fraction also revealed reduced expression of the R153Q mutant (−32%), suggesting decreased synthesis or increased degradation. Previous studies of recessive GLRA1 missense mutations in hyperekplexia showed reduced stability of receptor proteins resulting in reduced cell-surface accumulation. 36 The p.R153Q mutated residue is located in the N-terminal extracellular domain of the protein, consistent with a potential role in glycine binding and GlyR activation. To determine the functional properties of the two mutant GlyRs, we analyzed wholecell currents evoked by the application of glycine on transfected cells. As shown in Figure 2 , the minimum concentration of glycine able to evoke a whole-cell current was ∼ 100 times higher in cells expressing the GLRA2 R153Q mutant than in cells expressing the wild-type GlyR α2 subunit. Expression of GLRA2 R153Q was associated with a rightward shift in the dose-response curve, with a significantly higher EC50 value (mutant EC50 = 8.9 ± 0.9 mM, n = 7; wild type EC50 = 0.056 ± 0.002 mM, n = 13; Mann-Whitney U test, Po0.01; Figures 2b and c; Supplementary Table S5) , indicating a dramatically reduced sensitivity to glycine. This result implies that GlyRs containing the R153Q mutation are unlikely to be significantly activated in response to glycine release under physiological conditions in the developing CNS (⩽100 μM extracellular glycine). As expected, application of glycine at high concentration (30 mM) on cells expressing GLRA2 Δex8-9 did not evoke any current (n = 5), due to the lack of cell-surface expression of the deleted protein. To further study the effects of the R153Q substitution in Patient 2, we generated a homology model of the human GlyR α2 homomer. The model predicts that R153Q abolishes critical hydrogen bonds in the glycine-binding site, leading to the destabilization of the ligand-binding region and loss of function (Figures 2d and e) . Taken together, our results demonstrate that both the GLRA2 deletion and the R153Q mutation identified in patients with ASD dramatically impair GlyR α2 function in vitro.
ASD-associated mutations in GLRA2 fail to rescue axon defects caused by glra2 knockdown in zebrafish To assess whether the deletion and the R153Q mutation affect GLRA2 function in vivo, we knocked down the zebrafish ortholog glra2 and subsequently performed rescue experiments with human wild type or mutated GLRA2 transcripts. We first characterized a prominent and reproducible phenotype in 24-h post-fertilization (hpf) embryos injected with an antisense morpholino oligonucleotide targeted against a glra2 translation start site. The knockdown of glra2 led to obvious hyperbranching of spinal motor axons compared with controls (three independent experiments, n430 embryos per group; Figure 3a) . To ascertain the specificity of this defect of spinal motor neurons, we combined in situ hybridization experiments and reverse transcriptase PCR analysis on fluorescent-activated cell-sorted spinal motor neurons to confirm the presence of glra2 in this neuronal population (Supplementary Figure S4) , and performed rescue experiments by co-injecting human wild-type GLRA2 mRNA with glra2 morpholino. Human wild-type GLRA2 transcript fully rescued the multiple aberrant branching of zebrafish glra-depleted spinal motor neurons, confirming the specificity of the morphant phenotype. In contrast, injection of the deleted or mutated GLRA2 transcripts failed to rescue spinal motor neuron axon outgrowth defects in morphant embryos (four independent experiments, n440 embryos per group; Figures 3b and c) , establishing that both the deletion and the mutation disrupt the normal function of GLRA2 in vivo.
Glra2 knockout mice have impaired learning and memory and abnormal cortical synaptic plasticity Autism is associated with core social deficits as well as repetitive behaviors and/or restricted interests; however, additional cognitive and behavioral deficits are common, including intellectual disability, gross and fine motor deficits, and heightened anxiety. To further investigate the in vivo function of GlyR α2, we characterized male Glra2 knockout mice in a complete battery of behavioral tests assessing various aspects of brain function and ASD-related behaviors, including diverse social and motor abilities, anxiety, repetitive and stereotypic behaviors, learning and memory. Mutant mice had normal adult body and brain weight, were fertile, and had a normal life span. Locomotor activity in a novel cage and in the open field was similar in Glra2 − /Y and wildtype mice (Supplementary Figures S6a and b) . Motor coordination on the accelerating rotarod and motor strength in the wire hang test were both normal ( Supplementary Figures S6c  and d) . Anxiety-like behaviors, tested in the light-dark box and the elevated plus maze, were indistinguishable in hemizygous Glra2 − /Y mice and wild-type littermates (Supplementary Figures  S6e and f) . No differences between genotypes were observed in social behavior assessed in four tests: sociability (social versus inanimate preference test) and preference for social novelty (familiar versus stranger mouse), olfactory habituation/dishabituation to non-social and social odors, social interaction with juveniles and nest formation (Supplementary Figures S7a and d) . Similarly, no increase in repetitive behavior in the hole board and the marble burying tests was observed in Glra2 − /Y mice compared with wild-type animals ( Supplementary Figures S6g and h) . Furthermore, no enhanced stereotypies or abnormal grooming was observed in Glra2 mutant mice (not shown). For the complete statistical analyses of all behavioral tests, see Supplementary  Table S6 .
We next tested the learning and memory abilities of Glra2
mice. When assessed in the novel object recognition task, 10 min after the familiarization phase, wild-type mice spent significantly more time exploring the novel object, whereas Glra2 − /Y mice showed no preference (Figure 4a ), indicating impaired short-term memory. This deficit was confirmed in three additional cohorts of mice and was also observed in the long-term memory version of the task, after a delay of 24 h (Figure 4a ), indicating that Glra2 − /Y mice have short-term and long-term memory impairments. In contrast, Glra2 − /Y mice did not display deficits in spatial learning in the novel location recognition test, either 10 min or 24 h after the familiarization phase (Figure 4b ). To further assess the spatial learning and memory of Glra2 − /Y mice, we evaluated their performance in the Morris water maze. Mean escape latencies to find the platform during training in the hidden-platform task indicated similar spatial learning in wild-type and mutant mice (Supplementary Figure S8a) . Moreover, both genotypes spent significantly more time in the target quadrant during memory probe trials conducted either 10 min (Figure 4c ) or 24 h after training (Supplementary Figures S8b and c) . During reversal training, both genotypes learned the new platform location within 2 days and showed similar selective quadrant search in the probe trials (Figure 4c, Supplementary Figures S8b and c) . In conclusion, Glra2 − /Y mice showed impaired learning and memory in the novel object recognition task, whereas spatial learning and memory in the novel location recognition task and in the Morris water maze were normal.
To test whether the disruption of Glra2 altered synaptic plasticity, we measured long-term potentiation in prefrontal cortex slices prepared from Glra2 -/Y and wild-type mice. After high-frequency stimulation, we observed that long-term potentiation was significantly impaired in Glra2 mutant mice compared with controls ( Figure 4d ). These findings suggest that defective glycinergic signaling results in abnormal plasticity in the prefrontal cortex, a region consistently implicated in ASD.
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DISCUSSION
Given the extreme locus heterogeneity in ASD, it can be very challenging to identify sufficient repeated instances of mutations in the same gene to determine pathogenicity. Additional lines of evidence are therefore required to identify disease-causing variants and understand their functional impact. Combining genetic analysis and extensive functional studies represents a powerful strategy to identify genes, while providing insights into the molecular mechanisms underlying ASD.
In vitro functional characterization of the GLRA2 deletion and missense mutation identified in two patients with ASD revealed two mutational mechanisms. The GLRA2 deletion prevented cellsurface expression of GlyR α2 due to the loss of TM3 and TM4 domains. The R153Q mutation did not appear to impair plasma membrane expression in confocal immunofluorescence analysis, but quantification using biotinylation assays revealed markedly reduced cell-surface expression of the receptor. In addition, R153Q dramatically reduced glycine sensitivity, presumably through the disruption of hydrogen bonds with T238 that are required to stabilize the ligand-binding region. Of note, substitution of the equivalent amino acid in GLRA1, p.R147 (referred in the literature as p.R119 when numbered without the signal peptide), in sitedirected mutagenesis studies, also led to a dramatic reduction in apparent glycine affinity. 40, 41 Our data are consistent with previous studies showing that most hyperekplexia-causing mutations in GLRA1 and GLRB result either in disrupted surface expression or altered glycine efficacy. 42 Overall, our results demonstrate that GLRA2 mutations identified in patients with ASD lead to a loss of function of GlyR α2, either by affecting its subcellular localization or by reducing agonist sensitivity.
Our loss-of-function and rescue analyses during development of the zebrafish further confirmed the significant impact of the deletion and R153Q missense mutation on the function of GlyR α2 in vivo. 43 The knockdown of GLRA2 zebrafish ortholog resulted in a prominent defect of spinal motor axon outgrowth and branching, in agreement with a previous in vitro study showing that the blockade of GlyR increased neurite outgrowth in mouse embryonic spinal neurons. 24 Notably, the aberrant hyperbranching of zebrafish glra2-depleted spinal neurons was fully rescued by ) or mutated (mRNA α2R153Q ) versions of the transcript failed to rescue the abnormal axon phenotype. Data represent mean ± s.e.m. *P o0.05, **Po 0.01, ***P o0.001. ASD, autism spectrum disorder.
Rare GLRA2 mutations in autismhuman wild-type GLRA2, while mutant or deleted GLRA2 failed to rescue the axon branching phenotype. This set of experiments demonstrates in vivo that both the deletion and R153Q mutation identified in ASD patients act through a loss-of-function mechanism, and further supports their pathogenic nature. Moreover, our approach illustrates the value of using the zebrafish as an in vivo tool to characterize the pathogenic impact of novel genetic variants in neurodevelopmental disorders.
The behavioral characterization of Glra2 knockout mice showed specific impairments in short-term and long-term recognition memory in the novel object recognition task. However, their spatial learning and memory remained similar to wild-type mice when assessed in the novel location recognition task or the Morris water maze. The specific deficit in recognition memory with normal spatial learning may result from the distinct contribution of GlyR α2 in the brain regions and circuits underlying these forms of learning and memory. Although lesion and pharmacological studies indicate that the perirhinal cortex and hippocampus are necessary for object recognition memory, [44] [45] [46] analyses of neuronal activity marker expression and synaptic signaling implicate the prefrontal cortex in this form of memory. [47] [48] [49] In addition, transplantation of GABAergic precursor cells into the prefrontal cortex of mice prevents object recognition memory defects induced by the NMDA receptor antagonist phencyclidine, 50 confirming a role for the prefrontal cortex in this task and demonstrating a crucial contribution of inhibitory interneurons (see below). Thus, the memory deficit in the novel object recognition task may be the consequence of a prefrontal cortex dysfunction in Glra2 knockout mice, a hypothesis that is supported by the altered synaptic plasticity observed in this brain region. In contrast, the absence of deficits in spatial memory suggests that the loss of Glra2 does not affect relevant hippocampal functions. Altogether, the phenotype of Glra2 knockout mice is in keeping with the observation that individuals with ASD typically have preserved visuospatial abilities but exhibit deficits in executive function, especially in attention and working memory. 38, 51 In humans and mice, GLRA2 expression increases rapidly in the cortex during embryonic development, then decreases after birth and remains low in the adult (Supplementary Figure S9) . This spatiotemporal pattern, along with the developmental shift from excitatory to inhibitory action of GlyRs, 14 suggests a functional role of GlyR α2 in cortical development. Interestingly, disruption of Glra2 in mice leads to marked deficits in tangential interneuron migration in the developing cerebral cortex. 25 This observation could provide a mechanistic substrate underlying the synaptic dysfunction and aberrant learning and memory behavior we observed in adult Glra2 mutant mice. These results are in line with a growing body of evidence that supports a link between dysfunction of cortical inhibitory circuits and neuropsychiatric disorders, including epilepsy, schizophrenia, autism and intellectual disability. 52 Recent studies in animal models of ASD revealed specific interneuron defects and abnormal inhibitory neurotransmission (for example, Nlgn3, Cntnap2, Fmr1 and Mecp2). [52] [53] [54] [55] Significantly, whereas GABAergic neurotransmission has been repeatedly implicated in models of autism, 54, 56, 57 the present work implicates the glycinergic system as a novel pathophysiological mechanism in ASD. GlyR α2 has also been shown to play a role in the development of excitatory projection neurons in the cortex, since Glra2 knockout in mice impairs the proliferation and specification of cortical progenitors and leads to a reduction of cortical projection neurons 26 . These results further extend the role of GLRA2 in different aspects of cortical development, including proliferation, differentiation and cell migration. The disruption of GLRA2 is likely to result in an imbalance between excitation and inhibition, by the inability to provide appropriate inhibition or excitation in cortical neuronal networks. Disruption of the excitatory-inhibitory circuit balance has emerged as a common neurophysiological substrate underlying ASD and other neurodevelopmental disorders, 58, 59 a hypothesis supported by experimental observations in animal models. 52, [60] [61] [62] Hyperekplexia is a rare neurological disorder characterized by exaggerated startle responses to auditory or tactile stimuli, and 
). (d) Glra2
−/Y mice exhibited impaired long-term potentiation in the prefrontal cortex (n = 14 slices from nine WT mice, 10 slices from six Glra2 −/Y mice). Data represent mean ± s.e.m. *P o0.05, **P o0.01, ***P o0.001. AdjL, adjacent left quadrant; AdjR, adjacent right quadrant; Opp, opposite to target quadrant; Target, target quadrant; fEPSP, field excitatory postsynaptic potential. neonatal hypertonia. Three major genes have been implicated: the GlyR subunits GLRA1 and GLRB, and the presynaptic glycine transporter type 2, SLC6A5, with both dominant and recessive mutations reported. 42 Although classically considered a neuromotor disorder with normal cognitive function, recent studies in hyperekplexia have shown that learning difficulties and developmental delay are frequent, present in 40-80% of subjects, depending on the affected gene and the mode of inheritance.
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In particular, speech acquisition is frequently delayed. These findings strongly support the role of glycinergic transmission in neurocognitive development.
In conclusion, we used a combination of genetics and functional studies to demonstrate that GLRA2 mutations resulting in loss of function are associated with ASD, language delay and cognitive impairment in humans. Our in vivo studies of GLRA2 in zebrafish and mice uncovered novel biological roles of this gene beyond neurotransmission, in axon branching, cognition and synaptic plasticity. We anticipate that screening of large cohorts of individuals with ASD and other neurodevelopmental conditions will identify additional GLRA2 mutations, as illustrated by the de novo missense mutation (p.N136S) in GLRA2 found in a male with ASD in a recent whole-exome sequencing study. 5 We show here that this novel mutation substantially reduced surface expression (Supplementary Figure S4) and glycine sensitivity (Supplementary Figure S11) . In agreement with these findings, mutagenesis studies identified the equivalent residue in GLRA1, p.N130 (p. N102 when numbered without the signal peptide) to be crucial for ligand binding. 63 Overall, our findings provide new insights into the biological roles of GLRA2, and implicate altered GlyR α2-dependent mechanisms in ASD-related phenotypes.
